Functional energetics of cd4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Haghikia, Aiden ^a   Perrech, Moritz ^a   Pula, Bartosz ^a   Ruhrmann, Sabrina ^a   Potthoff, Anja ^a   Brockmeyer, Norbert H ^a   Goelz, Susan ^b   Wiendl, Heinz ^c   Lindå, Hans ^d   Ziemssen, Tjalf ^e   Baranzini, Sergio E ^f   Käll, Tor Björn ^g   Bengel, Dietmar ^h   Olsson, Tomas ⁱ   Gold, Ralf ^a   Chan, Andrew ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b BIOGEN   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g STOCKHOLM SÖDER HOSPITAL   (Sweden)

^h Neurologic Clinic Oberschwabenklinik   (Germany)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; EFALIZUMAB; FUMARIC ACID; MONOCLONAL ANTIBODY; NATALIZUMAB; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL ASSAY; CELL ENERGY; CELL SELECTION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HERPES SIMPLEX ENCEPHALITIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIPLE SCLEROSIS; OPPORTUNISTIC INFECTION; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RISK ASSESSMENT; CASE CONTROL STUDY; CLINICAL TRIAL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; PHASE 3 CLINICAL TRIAL;

HERPES;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;

EID: 79955424380     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018506     Document Type: Article

References (41)

1. Khalili K, White MK, Lublin F, Ferrante P, Berger JR, (2007) Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 68: 985-990.
2. Thurnher MM, Post MJ, Rieger A, Kleibl-Popov C, Loewe C, et al. (2001) Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy. AJNR Am J Neuroradiol 22: 977-984.
3. Gray F, Chrétien F, Vallat-Decouvelaere AV, Scaravilli F, (2003) The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 62: 429-440.
4. Major EO, (2009) Reemergence of PML in Natalizumab-Treated Patients - New Cases, Same Concerns. N Engl J Med 361: 1041-1043.
5. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, et al. (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10: 816-824.
6. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, et al. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834-4840.
7. Clifford DB, Deluca A, Simpson DM, Arendt G, Giovannoni G, et al. (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9: 438-446.
8. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, et al. (2004) A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127: 1970-1978.
9. Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, et al. (2009) Treatment of severe Progressive Multifocal Leukoencephalopathy associated with natalizumab monotherapy. N Engl J Med 361: 1075-1080.
10. Lindå H, v Heijne A, Major EO, Berg J, Olsson T, et al. (2009) Progressive Multifocal Leukoencephalopathy after treatment with Natalizumab as monotherapy in a Patient with Multiple Sclerosis. N Engl J Med 361: 1081-1087.
11. Koralnik IJ, (2002) Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy. J Neurovirol 8: 59-65.
12. Gasnault J, Kahraman M, de Goër de Herve MG, Durali D, Delfraissy JF, et al. (2003) Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 17: 1443-1449.
13. Berger JR, (2003) JCV-specific CD4 T cell response: another piece of the puzzle in explaining some aspects of AIDS associated PML. AIDS 17: 1557-1559.
14. Kalams SA, Walker BD, (1998) The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188: 2199-2204.
15. Koralnik IJ, Du Pasquier RA, Kuroda MJ, Schmitz JE, Dang X, et al. (2002) Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 168: 499-504.
16. Du Pasquier RA, Kuroda MJ, Schmitz JE, Zheng Y, Martin K, et al. (2003) Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy. J Virol 77: 11918-11926.
17. Fox CJ, Hammerman PS, Thompson CB, (2005) Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 5: 844-852.
18. Sottong PR, Rosebrock JA, Britz JA, Kramer TR, (2007) Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol 7: 307-311.
19. Nickel P, Bestard O, Volk HD, Reinke P, (2009) Diagnostic value of T-cell monitoring assays in kidney transplantation. Curr Opin Organ Transplant 14: 426-431.
20. Batal I, Zeevi A, Heider A, Girnita A, Basu A, et al. (2008) Measurements of global cell-mediated immunity in renal transplant recipients with BK virus reactivation. Am J Clin Pathol 129: 587-591.
21. De Luca G, Lugaresi A, Iarlori C, Marzoli F, Di Iorio A, et al. (1999) Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 95: 190-194.
22. Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC, (2006) Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 63: 930-935.
23. Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC, (2006) Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 63: 1066-1071.
24. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911-923.
25. Falchi AM, Isola R, Diana A, Putzolu M, Diaz G, (2005) Characterization of depolarization and repolarization phases of mitochondrial membrane potential fluctuations induced by tetramethylrhodamine methyl ester photoactivation. FEBS J 272: 1649-1659.
26. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, et al. (2010) Anti-JC Virus Antibodies: Implications for PML Risk Stratification. Ann Neurol 68: 295-303.
27. Kleinschmidt-DeMasters BK, Tyler KL, (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369-374.
28. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D, (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353: 375-381.
29. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362-368.
30. Khatri BO, Man S, Giovannoni G, Koo AP, Lee JC, et al. (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72: 402-409.
31. Dau PC, (1990) Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease. J Neuroimmunol 30: 15-21.
32. Tchilian EZ, Owen JJ, Jenkinson EJ, (1997) Anti-alpha 4 integrin antibody induces apoptosis in murine thymocytes and staphylococcal enterotoxin B-activated lymph node T cells. Immunology 92: 321-327.
33. Leussink VI, Zettl UK, Jander S, Pepinsky RB, Lobb RR, et al. (2002) Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis. Acta Neuropathol 103: 131-136.
34. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm199872.htm.
35. Martin MD, Cravens PD, Winger R, Frohman EM, Racke MK, et al. (2008) Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab. Arch Neurol 65: 1596-1603.
36. Martin MD, Cravens PD, Winger R, Kieseier BC, Cepok S, et al. (2009) Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 66: 1016-1020.
37. Yao K, Gagnon S, Akhyani N, Williams E, Fotheringham J, et al. (2008) Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS ONE 3: 2028.
38. Berger JR, (2006) Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 65: 48-53.
39. Boster A, Hreha S, Berger JR, Bao F, Penmesta R, et al. (2009) Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol 66: 593-599.
40. Gold R, Jawad A, Miller DH, Henderson DC, Fassas A, et al. (2007) Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol 187: 156-158.
41. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, et al. (2003) Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 17: 77-88.